No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NNVC Nanoviricides
- 2.400
- -0.030-1.23%
Close May 31 16:00 ET
- 2.460
- +0.060+2.50%
Post 19:51 ET
28.35MMarket Cap-2926P/E (TTM)
2.485High2.380Low156.55KVolume2.400Open2.430Pre Close380.64KTurnover1.39%Turnover RatioLossP/E (Static)11.81MShares2.48552wk High2.66P/B27.05MFloat Cap1.00052wk Low--Dividend TTM11.27MShs Float262.500Historical High--Div YieldTTM4.33%Amplitude1.000Historical Low2.431Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NanoViricides Elaborates On Its Development Of A First-in-class, Broad-spectrum Antiviral Agent That Could Revolutionize Treatment Of Viral Infections Including RSV, COVID, Influenzas And Other Viruses
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
Novel Host-Mimetic, Virus Killing Technology Platform SHELTON, CT / ACCESSWIRE / May 29, 2024 / NanoViricides, Inc. , a clinical-stage global leader in broad-spectrum antiviral
NanoViricides CEO Says Lead Asset NV-387 Could Be 'holy Grail' of Antiviral Medicines | NYSE-A:NNVC
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.
Analyzing Nanoviricides' Shift to RSV Treatments With Proactive Healthcare Analyst Dr. John Savin | NYSE-A:NNVC
Lethally RSV Infected Animals Orally Treated With NV-387 Showed Normal Lung Histology, Indicating Potential Cure
NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company
Comments
$Nanoviricides(NNVC.US$
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, a leader in broad-spectrum antiviral nanomedicines, has developed NV-387, a first-in-class antiviral agent targeting RSV, COVID-19, Influenza, and other viruses. NV-387 employs novel host-mimetic technology to remain effective despite viral mutations. It has outperformed existing drugs such as remdesivir, T...
$Nanoviricides(NNVC.US$
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
1
2
$Nanoviricides(NNVC.US$
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
1
1
$Scynexis(SCYX.US$
$Nanoviricides(NNVC.US$
$Tenet Healthcare(THC.US$
I want to watch these the most, I think, and now to find stuff in a different sector..
$Nanoviricides(NNVC.US$
$Tenet Healthcare(THC.US$
I want to watch these the most, I think, and now to find stuff in a different sector..
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg